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The Natural Course of Infantile Pompe’s Disease: 20 Original Cases
Compared With 133 Cases From the Literature
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G. Peter A. Smit#; Bwee-Tien T. Poll-The**; Henk D. Bakker‡‡; M. Christa B. Loonen‡;
Johannis B. C. de Klerk*; Arnold J. J. Reuser§; and Ans T. van der Ploeg*
ABSTRACT. Objective. Infantile Pompe’s disease is a
lethal cardiac and muscular disorder. Current develop-
ments toward enzyme replacement therapy are promis-
ing. The aim of our study is to delineate the natural
course of the disease to verify endpoints of clinical stud-
ies.
Methods. A total of 20 infantile patients diagnosed by
the collaborative Dutch centers and 133 cases reported in
literature were included in the study. Information on
clinical history, physical examination, and diagnostic pa-
rameters was collected.
Results. The course of Pompe’s disease is essentially
the same in the Dutch and the general patient popula-
tion. Symptoms start at a median age of 1.6 months in
both groups. The median age of death is 7.7 and 6
months, respectively. Five percent of the Dutch patients
and 8% of all reported patients survive beyond 1 year of
age. Only 2 patients from literature became older than 18
months. A progressive cardiac hypertrophy is character-
istic for infantile Pompe’s disease. The diastolic thick-
ness of the left ventricular posterior wall and cardiac
weight at autopsy increase significantly with age. Motor
development is severely delayed and major developmen-
tal milestones are generally not achieved. For the Dutch
patient group, growth deviates significantly from normal
despite start of nasogastric tube feeding. Levels of aspar-
tate aminotransferase, alanine aminotransferase, lactate
dehydrogenase, creatine kinase, or creatine kinase-myo-
cardial band isoenzyme are typically elevated, although
aspartate aminotransferase, alanine aminotransferase,
and lactate dehydrogenase increase significantly with
age. The patients have fully deleterious mutations. Acid
-glucosidase activity is severely deficient.
Conclusions. Survival, decrease of the diastolic thick-
ness of the left ventricular posterior wall, and achieve-
ment of major motor milestones are valid endpoints for
therapeutic studies of infantile Pompe’s disease. Muta-
tion analysis and measurement of the -glucosidase ac-
tivity should be part of the enrollment program. Pediat-
rics 2003;112:332–340; Pompe’s disease, -glucosidase,
acid maltase, enzyme replacement, glycogen storage dis-
ease type II.
ABBREVIATIONS. ASAT, aspartate aminotransferase; ALAT, ala-
nine aminotransferase; CK, creatine kinase; LDH, lactate dehydro-
genase; CK-MB, creatine kinase-myocardial band isoenzyme;
LVPWd, left ventricular posterior wall was measured at the dias-
tole; CRIM, cross-reactive immunologic material; EKG, electrocar-
diogram; MRI, magnetic resonance imaging.
Pompe’s disease, or glycogen storage diseasetype II, is a lysosomal storage disorder inwhich deficiency of acid -glucosidase leads to
accumulation of glycogen and finally to destruction
of muscle tissue. Complete deficiency of -glucosi-
dase causes a progressive lethal cardiac and skeletal
muscle disorder known as infantile Pompe’s dis-
ease.1 Partial deficiency leads to a milder late onset
phenotype. The latter condition may present at any
age and is subdivided in nonclassical infantile, child-
hood, juvenile, and adult Pompe’s disease.2–4 The
estimated combined incidence is 1:40.000 births.5,6
There is as yet no registered therapy for Pompe’s
disease, but the first clinical studies on enzyme re-
placement therapy with recombinant human -glu-
cosidase from rabbit milk and Chinese hamster
ovary cells have started. The preliminary data of
phase II studies in infantile patients are promising.7–9
However, to fully appreciate the effect of enzyme
therapy, precise knowledge is needed on the natural
course of infantile Pompe’s disease. This information
is currently lacking.
Only 2 reviews on infantile Pompe’s disease were
published over the last 50 years. One review dates
from 1950 and describes 14 patients.10 The other
review is from 1962 and describes 40 additional cas-
es.11 Notably, these reviews date from the time that
the primary enzyme defect was still unknown.12
This review depicts the natural course of classic
infantile Pompe’s disease based on original data
from 20 patients who where seen by the Dutch col-
laborative centers between 1980 and 1998 and a col-
lection of 133 cases from the literature.
METHODS
We analyzed the clinical and laboratory data of the patients
who were biochemically or genetically diagnosed with infantile
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Pompe’s disease at the department of Clinical Genetics of the
Erasmus University Rotterdam between 1980 and 1998. These data
were compared with those obtained from the literature. We in-
cluded all publications identified via Pubmed by a search for
“infantile Pompe’s disease,” “infantile acid maltase deficiency,”
“infantile glycogenosis type 2,” “infantile -glucosidase deficien-
cy,” and “glycogenosis type 2a”, written in English, German,
French, Dutch, or Italian. Case reports cited in the collected articles
and additional ones cited by Hirschhorn and Reuser1 were added.
We excluded publications lacking clinical information and cases of
normal -glucosidase activity (Danon’s disease), prenatal death,
and experimental treatment.
Information on clinical history, physical examination, and di-
agnostic data were collected. Data were often incomplete. Symp-
toms or findings of physical examination that were not reported
were scored as negative.
Biochemical-Genetic Studies
Fibroblasts were homogenized in water, and 2000  g super-
natants were used to determine -glucosidase activity.13,14 Muta-
tion analysis was performed using genomic and cDNA, as de-
scribed earlier.15 The functional effect of mutations was studied by
assay of -glucosidase synthesis and activity in transiently trans-
fected SV40 transformed monkey kidney cells or in cultured fibro-
blasts of patients.15,16
Growth
Data on growth were collected and expressed in the standard
deviation score for weight ([weight of the patient  weight ac-
cording to the P50 for height]/standard deviation).
Clinical Chemistry
Aspartate aminotransferase (ASAT), alanine aminotransferase
(ALAT), and creatine kinase (CK) were measured according to the
guidelines of the International Federation of Clinical Chemistry.
Lactate dehydrogenase (LDH) was measured according to the
guidelines of the Dutch Association of Clinical Chemistry. Creat-
ine kinase-myocardial band isoenzyme (CK-MB) was measured
by immune inhibition. All measurements were performed at an
assay-temperature of 37°C.
Cardiology
The thickness of the left ventricular posterior wall was mea-
sured at the diastole (LVPWd) by M-mode echocardiography in
compliance with the guidelines of the American Society of echo-
cardiography.17
Statistics
Characteristics for which repeated measurements within pa-
tients were available (weight, length, enzyme activities, LVPWd)
were analyzed using mixed model analysis of variance (random
coefficients model for SAS PROC MIXED). Correlation coefficients
given are Spearman rs. Data given are medians, or indicated
otherwise. Two-sided P values  .05 were considered significant.
RESULTS
Population
Twenty infantile Pompe patients were diagnosed
between 1980 and 1998; 14 patients were from Dutch,
4 from Turkish, 1 from Italian, and 1 from Taiwanese
ancestry. The patients were admitted to 5 academic
hospitals (Beatrix Clinic Groningen, Wilhelmina
Children’s Hospital Utrecht, University Medical
Center Nijmegen, Emma Children’s Hospital Am-
sterdam and the Sophia Children’s Hospital Rotter-
dam). Thirty percent of the patients was female, 70%
male. In literature we located 83 publications de-
scribing 133 patients, 42% female, 50%
male.2,10,11,18–97 Sex was not reported in 8% of the
cases.
Molecular Characterization
All patients identified via the Department of Clin-
ical Genetics Rotterdam had a severe -glucosidase
deficiency (Table 1). The median activity in fibroblast
was 0.52 nmol MU/hour/mg protein (range: 0.18–
1.15 nmol/hour/mg protein, normal value 36–166
nmol MU/hour/mg protein, median 84 nmol MU/
hour/mg, n  254). In 15 patients, we identified the
mutations in both -glucosidase alleles. In 2 more
patients, 1 mutation was detected (Table 1). In total,
9 different mutations were found. The effect of 7
mutations was known: delT525,98 del exon18,23
Asp645His,58,99 insC2741/insG2743,15 Pro768Arg,15
del Lys903,100 and Gly309Arg.101 All these mutations
are fully deleterious and result in severe deficiency
of -glucosidase activity. Two new mutations were
TABLE 1. -Glucosidase Activity, Mutations in the Lysosomal -Glucosidase Gene, and the Resulting Amino Acid Changes per
Patient
Patient -Glucosidase
Activity
Nucleotide
Change
AA Alteration CRIM Nucleotide Change AA Alteration CRIM*
1 1.15 DelT525110 Thr1753shift  Unknown
2 0.59 DelT525110 Thr1753shift  Unknown
3 0.43 DelT525110 Thr1753shift  DelT525110 Thr1753shift 
4 0.29/0.42 DelT525110 Thr1753shift  DelT525110 Thr1753shift 
5 0.38 DelT525110 Thr1753shift  InsA1827 Tyr609Ter 
6 0.33 DelT525110 Thr1753shift  Del exon18111 Del 55aa 8283 
7 1 DelT525110 Thr1753shift  Del exon18111 Del 55aa 8283 
8 Undetectable DelT525110 Thr1753shift  Del exon18111 Del 55aa 8283 
9 0.18 Del exon18111 Del 55aa 8283  Del exon18111 Del 55aa 8283 
10 Not available Del exon18111 Del 55aa 8283  Del exon18111 Del 55aa 8283 
11 0.44 Del exon18111 Del 55aa 8283  2639C3A Ala880Asp 
12 Undetectable Del exon18111 Del 55aa 8283  3 nucleotide deletion Del Lys903100 
13 0.6 Del exon18111 Del 55aa 8283  925G3A101 Gly309Arg 
14 0.73 1933G3C58 Asp645His  1933G3C58 Asp645His 
15 0.7 2741AG3CAGG15 Frameshift  2741AG3CAGG15 Frameshift 
16 1.1 2741AG3CAGG15 Frameshift  2741AG3CAGG15 Frameshift 
17 0.52 2303C3G15 Pro768Arg  2303C3G15 Pro768Arg 
18 1.1 Unknown Unknown
19 0.2 Unknown Unknown
20 0.23 Unknown Unknown
* Presence (CRIM) or absence (CRIM) of immunologically detectable -glucosidase.
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detected: Ala880Asp and InsA1827, resulting in
Tyr609Ter. The latter mutation will certainly lead to
loss of function. The effect of Ala880Asp was studied
in transiently transfected SV40 transformed monkey
kidney cells, and also leads to complete loss of -glu-
cosidase activity. The delT525 and del exon18 muta-
tions were found most frequently, 10 times each. In
all but 1 case the patient was from Dutch ancestry.
One patient from Italy was homozygous for the
exon18 deletion. Her parents came from the Italian
region of Catania where this mutation prevails as in
the Dutch population.102 Of all mutations found in
the Dutch patient group, the delT525 mutation, the
insC2741/insG2743 mutation, and the Tyr609Ter
mutation result in absence of cross reactive immu-
nologic material ([CRIM]-negative). The delT525 mu-
tation leads to frame shift and formation of unstable
messenger. Two patients are homozygous for this
mutation, and therefore completely CRIM-negative.
Two of the 4 patients from Turkish ancestry are
homozygous for the insC2741/insG2743 mutation
and therefore also CRIM-negative. Both these pa-
tients were offspring of a consanguineous marriage.
Another Turkish patient was homozygous for the
Pro768Arg mutation, whereas in the fourth Turkish
patient the mutation is as yet unknown. One patient
from Taiwan appeared homozygous for the G1933C
mutation known to occur in infantile patients from
Taiwan and certain areas of China.58,99 The great
majority of case reports from literature is incomplete
as to investigating the patients genotype. Related
literature data are therefore not included in this re-
view.
Course of Disease
First symptoms were noted at a median age of 1.6
months in both the Dutch patient group and in liter-
ature 2,10,11,18,20,21,23,25,27–38,40–46,48–60,62,63,65–76,78–88,91–96,99
(Table 2). Patients were hospitalized at median ages
of 2.8 months in the Dutch patient group and 4.0
months in literature,10,11,18–21,24,26,27,29,30,33,34,36–38,40–
46,48,51–53,55,61–63,65,68,70,72,74,78,80,82,84,87,89,90,92,95–97,103 and
diagnosed at respective ages of 5.3 and 4.5
months.2,11,18,22,25,27,28,32,41,44,46,47,58,61,66,73,80,83,85,91,93,99
The median time from diagnosis to death was 2 months
in both groups.2,11,18,22,25,27,28,32,41,44,46,61,73,80,83,85,91,93 In
the Dutch patient group, death occurred at a median
age of 7.7 months. Patients described in literature
died at a median age of 6.0 months.2,10,11,18–21,23–34,36–
44,46,48–57,59–65,67–75,78–97 The survival curve of both
groups is presented in Fig 1. Only 1 Dutch infant
survived beyond 1 year of age. This infant was born
prematurely at a gestational age of 32 weeks. The age
corrected for the duration of gestation was 10.6
months. The patients described in literature died in
majority within the first year of life (109 of 119 pa-
tients). Ten patients survived beyond 1 year of
age.2,19,29,38,56,61,85,91,97 Only 2 patients were reported
with ages of death above 1.5 year (29 and 34.5
months).38,97
In the Dutch patient group, the clinical course of
the CRIM-negative patients did not differ from the
CRIM-positive patients. The 5 CRIM-negative pa-
tients died between 6.6 and 8.6 months of age.
Clinical History: First Symptoms
We kept record of the first symptoms of all Dutch
patients. Information on an additional 66 cases was
available from the literature.2,10,11,18–20,22–24,26–32,34–
38,41,42,44,45,48 –52,55–58,60 –76,78,79,81,82,84,85,87,88,92,95–97,99,
104–106 Feeding problems and/or failure to thrive
were the first symptoms in 55% of the Dutch patients
and in 44% of the cases reported in literature. Motor
problems, like muscular weakness, motor retarda-
tion, and paucity of movements, were the first symp-
tom in 40% of the Dutch patient group and in 20% of
the cases described in literature. Respiratory prob-
lems (like airway infections and respiratory diffi-
culty) were the first symptom in 40 and 27% of the
cases. Cardiac problems (like cardiac failure and
rhythm disturbances) were noticed as first symptom
in 15% of the Dutch patients and in 23% of the cases
from literature (the total percentage exceeds 100%
because patients may present with combinations of
first symptoms).
Other less frequently reported symptoms were
Fig 1. Survival curve of patients with infantile Pompe’s disease.
The Dutch patient population (solid line) and the literature cases
(dashed line) are illustrated separately.
TABLE 2. Course of Disease of the Dutch Population and of the Cases Collected From Literature
The Netherlands Literature
Median* Mean* Range* N Median* Mean* Range* N
20 133
First symptoms 1.6 1.9 0–6.8 20 1.6 2.1 0–11 107
Hospitalization 2.8 3.4 0–7.3 20 4.0 4 0–14 77
Diagnosis 5.3 4.8 0.6–9.3 20 4.5 5.4 0–23 22
Death 7.7 7.6 3.8–12.4 20 6.0 6.3 0–34.5 119
Time from diagnosis to death 2.0 2.8 0.1–6.4 20 2.0 2.7 0–10 18
* The age of the patients is given in months.
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discomfort (like malaise, sweatiness, fatigue, irrita-
bility, and a weak cry) and gastrointestinal com-
plaints (like constipation, vomiting, and regurgita-
tion). Neurologic symptoms like spasm and tremor
were noticed in 2 Dutch cases. In 3 cases from liter-
ature, mental retardation was suspected.27,38,75 Rea-
sons for hospitalization were respiratory problems,
cardiac problems, feeding problems, and growth re-
tardation in decreasing order.
Physical Examination
The 20 Dutch patients were physically examined.
An additional 103 physical examination reports were
available from literature.2,10,11,18–23,26–42,44–46,48–52,55–
57,59–65,67–74,76–79,81,82,84,85,87,88,92,95–97 At first sight,
patients were tachy- or dyspnoeic (75% of the Dutch
patients and 41% of the cases from literature), pale
(40% of the Dutch patients, 20% of the cases de-
scribed in literature), and/or cyanotic (30% and 23%,
respectively). An enlarged tongue was noticed in
45% of the Dutch patients and 29% of the cases from
literature. The Dutch patients typically were hypo-
tonic (95%). Hypotonocity was reported to a lesser
extent in literature (52%). In 75% of the Dutch pa-
tients and in 46% of the cases from literature, a heart
murmur was present. A gallop rhythm was reported
in 17% of the cases from the literature. Auscultation
of the lungs was abnormal in 55% of the Dutch
patient group and in 47% of the cases reported in
literature. At palpation of the abdomen a moderate
hepatomegaly was found in 90% of the Dutch pa-
tients and reported in 29% of the cases from litera-
ture (median size 3 and 3.2 cm below the costal
margin, respectively). A moderate splenomegaly
was found in 15 and 6% of the patients, respectively
(median size 2 cm below the costal margin in both
populations). Absent deep tendon reflexes (35% of
the Dutch patients, 33% of the cases from literature)
was the main abnormality observed during neuro-
logic examination. Incidentally, tongue fibrillations
(3%), absence of tongue movements (2%), and
spasms of the legs (2%) were reported in literature. In
the Dutch patient group these were not noticed.
Motor Development
A complete set of data on motor development was
available for 16 Dutch patients. None of these pa-
tients ever learned to turn, sit, or stand. Of the 133
patients reported in literature, only 2 patients were
reported to turn from supine to prone position.18,63
The age at which they achieved this motor milestone
was not mentioned, but they lost this ability at the
age of 4 and 7 months, respectively. Three patients
were reported to sit. One achieved this motor mile-
stone at the age of 6 months and subsequently lost it
at the age of 7 months.63 The other patients were
reported “no longer to sit without support” and “no
longer to support themselves in a sitting position” at
ages of 7.5 months72 and 10.5 months,33 respectively.
Growth
Longitudinal data on weight, length, and head
circumference were available for 18 of the Dutch
patients (mean duration of follow-up 4.3 months).
The standard deviation score for weight decreased
significantly with age (P  .001, Fig 2), showing a
deviation from the normal weight curve, despite the
start of nasogastric tube feeding in 14 patients. In-
crease of length and head circumference with age
was normal.
Clinical Chemistry
Levels of CK, CK-MB, LDH, ASAT, and ALAT
generally appeared to be increased in the Dutch pa-
tients (n  19). The median value of CK was 690 IU
(range: 175-2307 IU, upper limit of normal 295 IU
(P95), number of measurements 40). A normal CK
value was measured 5 times. The median value of
CK-MB was 29 (range: 14–64 IU, upper limit of
normal 18 IU, number of measurements 20). CK-MB
was normal in 3 measurements. The median value of
LDH was 1956 IU (range: 801-5714 IU, upper limit of
normal 1097 IU, number of measurements 35). LDH
was normal in 4 measurements. The median value of
ASAT was 321 IU (range: 115–859 IU, upper limit of
normal 89 IU, number of measurements 51) and of
ALAT 184 (range: 9–397 IU, upper limit of normal 60
IU). ASAT and ALAT were one time normal in one
patient, but elevated in later measurements. In none
of the cases normal values for CK, CK-MB, LDH,
ASAT, and ALAT were found at the same time.
There was a significant increase of LDH, ALAT, and
ASAT with age (P  .001, Fig 3). Data from literature
were too scarce to draw conclusions. Control ranges
and assay temperatures were often lacking.
Cardiology
All available chest radiographs of the Dutch pa-
tients (n  19) showed a cardiomegaly at ages rang-
ing from 0 to 7.2 months. In literature an increased
heart size was reported in 99% of the cases described
(n  82).10,11,18–21,26–42,44,45,48–52,55,56,60,61,63–68,70–72,74,
76–79,81–83,85,87,88,95,97,107
On the electrocardiograms (EKGs), a left ventricu-
lar hypertrophy was noticed in all Dutch patients
(n  19). A biventricular hypertrophy was seen in
84%, and an atrium hypertrophy in 11% of the pa-
tients. In literature, left ventricular hypertrophy was
Fig 2. Standard deviation score of weight versus age in weeks
(P  .001) for the Dutch patient population. Standard deviation
score  [weight of the patient-weight according to the P50 for
weight]/standard deviation of weight.
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reported in 60 (83%) of 72 cases.2,10,11,18,19,22,24,26,27,29,30,
32,34–41,44,45,49,50,52,55,56,60,61,63–68,70,72,76–79,81,83,85,87,88,95,97
In 10 cases, the cardiomegaly was noticed on the
chest radiograph, but not on the EKG. In only 2
patients, the EKG was totally normal.2,88 Atrium hy-
pertrophy was seen in 4% of the cases described in
literature.
Another EKG abnormality reported is a borderline
to shortened PQ-interval. This was present in 58% of
the Dutch patient group (median 0.08 seconds) and
in 51% of the cases described in literature (median
0.08 seconds). Repolarization disturbances like T-in-
version and ST-depression were present in 84% of
the Dutch and 56% of the literature cases.
Echocardiographic data of 18 Dutch patients were
available (Fig 4A). All patients had a cardiac hyper-
trophy at ages varying from 0.1 to 8.8 months, as
shown by the increased thickness of the left ventric-
ular posterior wall and the intra-ventricular septum.
The thickness of the left ventricular posterior wall
increased significantly with age (P  .01, Fig 4A). In
literature, the echocardiographic data of 23 patients
were presented.18,19,26,28,32,35,37,39,49,56,60,66,67,76,77,81,83,108
All patients had a cardiac hypertrophy, as illustrated
by the thickening of the left ventricular posterior
wall and/or intra-ventricular septum.
In 67 cases, heart-weight at obduction was re-
ported.10,11,18–21,24,26,27,29,30,33,34,36–38,40,41,44–46,48,51–53,
55,61–65,68,70,72,74,78,80,82,84,87,89,92,95–97 The heart weight
shows a significant increase with age (rs  0.57, Fig
4B) in accordance with the cardiac ultrasound data of
the Dutch patients. Outflow tract obstruction was
described in 8 cases from literature,11,32,39,45,49,76,83,109
as observed either by echocardiography, catheteriza-
tion, or autopsy (6%).
When all cardiac data from the literature are com-
piled there is information available for 109 patients;
107 of them have a cardiomegaly and 2 do not.2,88
Neurologic Diagnostics
Data on brain imaging were available for 8 of the
20 Dutch patients. An ultrasound of the brain was
performed in 6 patients, a magnetic resonance imag-
ing (MRI) in 2, and a computed tomography in 2
patients. The ultrasound was normal in all 6 patients.
A MRI performed in 1 of these patients was also
normal. Computed tomography made in 2 addi-
tional patients showed some widening of the ante-
rior horn of the left ventricle in one patient and a
possible widening of the peripheral liquor spaces in
the other patient. The MRI in the latter patient re-
vealed central and cortical atrophy.
DISCUSSION
With the phase II clinical studies on the effect of
enzyme replacement therapy in Pompe’s Disease un-
derway, it becomes increasingly important to
achieve accurate knowledge on the natural course of
the disease to verify endpoints. The first results of
enzyme replacement therapy in infants are promis-
ing. Patients seem to survive longer and an effect on
cardiac hypertrophy is observed. However, system-
atic surveys of larger groups of untreated patients,
needed to fully appreciate the effect, are lacking.
Fig 3. Increase of ASAT, ALAT, and LDH with age for the Dutch patient population (P  .001 for ASAT and ALAT, and P  .004 for
LDH).
Fig 4. A, Increase of the LVPWd with age (P  .01). B, Increase of heart weight with age (rs  0.57).
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Therefore, we followed the natural course of infantile
Pompe’s disease in 20 Dutch patients and studied the
published case reports of an additional 133 patients.
The Dutch patients were identified via the enzyme
diagnostic laboratory of the Department of Clinical
Genetics, Erasmus University, Rotterdam, thereby
precluding selection based on preset clinical criteria.
The literature data show that Pompe’s disease oc-
curs worldwide. The course of the disease is essen-
tially the same in the Dutch and the general patient
population. Symptoms start in both groups shortly
after birth (median age: 1.6 months). Age at hospi-
talization (2.8 and 4.0 months), diagnosis (5.3 and 4.5
months), and death (7.7 and 6.0 months) also com-
pare well.
All Dutch patients have a severe -glucosidase
deficiency of 1.5% of the median control value
(median 0.6% of control value) in fibroblasts. Patients
from Taiwanese, Turkish, Dutch, and Italian ancestry
are included. Mutations were discovered in 32 of 40
mutant alleles. All revealed fully deleterious muta-
tions. The frequently occurring IVS1 (13T3G) mu-
tation, typically associated with late-onset Pompe’s
disease was not present in the infantile patient
group. This finding is consistent with the prediction
that only the combination of 2 fully deleterious mu-
tations leads to the classical early-onset phenotype.
Patients from different ethnic origin had different
mutations. For instance, delT525 and del exon18
are common among the Dutch patients. We de-
tected 2 new severe mutations: Ala880Asp and
InsA1827 (leading to Tyr609Ter). Their effect was
demonstrated by expression studies. Currently,
80 fully deleterious mutations are known (www.
pompecenter.nl).
In both patient groups feeding problems, failure to
gain weight, muscular weakness, motor retardation,
cardiac problems, respiratory difficulty, and airway
infections were frequently reported as first symptom
of the disease. Once referred to the hospital, symp-
toms of respiratory and/or cardiac failure were evi-
dent. The children mostly were tachy- and/or dys-
pnoeic and often pale or cyanotic. On clinical
examination, a cardiac murmur was frequently
present. The moderate enlargement of the liver is
assumed to result from glycogen storage, but may
also result from cardiac decompensation. Hypotonic-
ity was noted as a prominent feature in the Dutch
patients, but is less reported in the literature. We
consider it unlikely that the Dutch and general pa-
tient group differ in this aspect and attribute the
apparent difference to incompleteness of the case
reports. Absence of deep tendon reflexes was the
most common abnormality on neurologic examina-
tion. Enlargement of the tongue was reported in less
than half of the patients (45% of the Dutch cases and
29% of the cases from literature).
The following findings are key elements for the
definition of the classical infantile subtype of Pompe
disease. First, infantile Pompe patients typically die
in the first year of life. Death occurs at a median age
of 7.7 months in the Dutch patient group and 6.0
months in literature. Similar survival data were re-
ported by Amalfitano et al7–9 (mean age of death 8.6
months) and Slonim et al2–4 (calculated median age
of death 8.0 months). There is no significant differ-
ence between the age of death of CRIM-negative and
CRIM-positive patients in the Dutch patient group. A
minority of patients became older than 1 year (8%).
Ninety-eight percent of all patients died before the
age of 1.5 years. None of the patients grew older than
2.9 years. Based on n  139, statistical calculation
shows that the upper limit of 95% confidence interval
for 3 years survival equals 3%.
Second, infants with classical Pompe’s disease
have a rapidly progressive cardiac hypertrophy. The
diastolic thickness of the left ventricular posterior
wall appears to be a good measure for follow-up. The
left ventricular mass or left ventricular mass index
might be used as follow-up on cardiac weight. In the
Dutch patients, a cardiomegaly was found at any
time point in life, even when the chest radiograph,
the electrocardiogram, or echocardiography was per-
formed at birth. This indicates that cardiac hypertro-
phy already develops during gestation. In literature,
107 of the 109 patients appeared to have a cardio-
megaly during cardiac evaluation. From the 2 pa-
tients from literature who were reported to have a
normal heart on EKG and chest radiograph, 1 had an
unusual high level of residual -glucosidase activity
(36% of normal in fibroblasts, and 46% of normal in
muscle), which does not combine with infantile
Pompe’s disease.88 The other patient had 2 brothers
who died at relatively advanced age (3 and 4 years of
age) as compared with all other cases in this study.2
From the combined data we conclude that the ab-
sence of cardiomegaly is atypical for classical2–4 in-
fantile Pompe’s disease.
Three other key elements of infantile Pompe’s dis-
ease are motor development, growth, and laboratory
findings. Motor development is severely delayed.
Important milestones are generally not achieved or
lost shortly after acquisition. None of the Dutch pa-
tients ever learned to turn, sit, or stand. In literature,
only 3 of the 133 patients were reported to turn or sit,
but subsequently lost this ability quickly.
Weight gain appears to be significantly reduced in
infantile patients, despite the start of nasogastric tube
feeding.
The levels of ASAT, ALAT, LDH, CK, and CK-MB
are typically elevated in infantile Pompe’s disease.
None of the Dutch patients has normal values for
ASAT, ALAT, LDH, CK, and CK-MB at the same
time. ASAT, ALAT, and LDH increase significantly
with age and appear an even better marker of disease
progression than CK. It is most likely that the en-
zymes originate from muscle. However, it is not
excluded that the liver contributes in part.
Based on the data obtained in our study on the
natural course of infantile Pompe’s disease, it is con-
cluded that survival is a good endpoint for enzyme
replacement therapy studies. In an ongoing open
label enzyme replacement therapy study, we cur-
rently treat 4 infantile Pompe patients with recombi-
nant human -glucosidase from rabbit milk.7–9 All 4
patients are still alive at the age of 3 years. Based on
this result, statistical calculations show that the 95%
confidence interval for the 3 years survival percent-
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age ranges from 40 up to 100% in a group of infantile
patients receiving enzyme therapy. This means that
if the enzyme therapy study with the same therapeu-
tic regimen would be repeated with a larger number
of infants, the 3-year survival percentage is expected
to be 40% at least. Comparing this figure with the
upper limit of the 95% confidence interval for 3 years
survival of untreated children (this manuscript),
which is 3%, there is a strong indication that enzyme
therapy has an effect on survival.
However, because optimization of care (like appli-
cation of artificial ventilation, treatment of infections,
and other supportive measures) also may prolong
survival of untreated children, the results obtained
with enzyme therapy should ideally be compared
with results obtained in a matched group of children,
who receive exactly the same supportive care but no
enzyme therapy.
Based on the assumption that 1-year survival in-
creases from 10% in the “placebo” group to at least
75% in the enzyme replacement therapy group, it is
calculated that in a placebo-controlled enzyme ther-
apy study 11 patients have to be included in both the
treatment and the placebo group to obtain 80%
power at   0.05 (Fisher exact test) for the compar-
ison of survival.
A decrease of cardiac hypertrophy, evidenced by a
decrease in the diastolic thickness of the left ventric-
ular posterior wall or left ventricular mass index can
provide additional proof for efficacy of therapy and
serve as secondary endpoint. Improvement of clini-
cal condition should accompany the latter finding to
demonstrate the clinical benefit for the patients.
Achievement of major milestones provides evidence
for the efficacy of enzyme therapy on motor function.
If for ethical reasons a non-placebo-controlled
study is performed and historical data are used as
control, it is of utmost importance that no selection
bias is introduced. In our opinion, molecular genetic
delineation of the patients should always be part of
the enrollment program, besides characteristic clini-
cal and cardiac features, to identify patients with
noninfantile phenotypes, who have a prolonged nat-
ural course.
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BLAME TECHNOLOGY FOR OBESITY
“Technology may be fattening. Something surely is. In the past quarter-century,
American waistlines have bulged, and obesity has become epidemic. The govern-
ment’s authoritative National Health Examination Survey found 30% of adults in
1999–2000 were obese by the technical medical definition. That’s up from 23% in
1988–1994 and 15% in 1976–1980. . . Some blame the food industry for deceiving us
into eating more fatty and caloric foods. Others link the increase in weight to the
decrease in smoking. Still others blame a sedentary lifestyle in which playing
games on computer screens replaces athletic activity, and cars and elevators
eliminate the need to walk. It’s obvious that technology has made us richer and
food cheaper, in terms of the hours we have to work to feed ourselves. And
technology has changed the physical nature of daily work.”
Wessel D. Wall Street Journal. February 13, 2002
Noted by JFL, MD
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